Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(17 sites)

China

Novartis Investigative Site, Guangzhou, Guangdong

Novartis Investigative Site, Zhengzhou, Henan

Novartis Investigative Site, Wuhan, Hubei

Novartis Investigative Site, Changchun, Jilin